The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
| 2 | H01 | Pituitary and hypothalamic hormones and analogues | |
| 3 | H01C | Hypothalamic hormones | |
| 4 | H01CC | Anti-gonadotropin-releasing hormones | |
| 5 | H01CC03 |
| Active Ingredient | Description | |
|---|---|---|
| Elagolix |
Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of elagolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ORILISSA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
